𝔖 Bobbio Scriptorium

✦ LIBER ✦

The feasibility and safety ofS-adenosyl-l-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial

✍ Scribed by Green, Tamar; Steingart, Lital; Frisch, Amos; Zarchi, Omer; Weizman, Abraham; Gothelf, Doron

Book ID: 118788865
Publisher: Springer
Year: 2012
Tongue: English
Weight: 211 KB
Volume: 119
Category: Article
ISSN: 1435-1463
DOI: 10.1007/s00702-012-0831-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of S-Adenosyl l-Methionine in

Evaluation of S-Adenosyl l-Methionine in a Double-Blinded, Randomized, Placebo-Controlled, Clinical Trial for Treatment of Presumptive Osteoarthritis in the Dog

✍ Darren J. Imhoff; Wanda J. Gordon-Evans; Richard B. Evans; Ann L. Johnson; Domin 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

Efficacy and safety of rebamipide for th

Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren’s syndrome: a double-blind placebo-controlled multicenter trial

✍ Susumu Sugai; Hiroki Takahashi; Shuji Ohta; Makoto Nishinarita; Masami Takei; Sh 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 413 KB

A multicenter, randomized, double-blind

A multicenter, randomized, double-blind placebo-controlled, single dose trial of the safety and efficacy of intravenous ibuprofen for treatment of pain in pediatric patients undergoing tonsillectomy

✍ Moss, Jonathan R.; Watcha, Mehernoor F.; Bendel, Laima P.; McCarthy, Denise L.; 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB